C.B. firm lands e-health contract

See original story
A New Waterford-based e-health software firm will manage phase one of the provincial wound care program redesign.
Health Outcomes Worldwide announced it has won the $207,000 contract from the Nova Scotia Department of Health and Wellness to design and implement the new program.
“We applaud the province of Nova Scotia for being one of the first in North America to consider a program that will undoubtedly improve wound care management for patients and health care providers alike,” said HOW founder Corrine McIsaac, adding,
“Our team is absolutely thrilled to be playing a key role in this process.”
With an initial term of one year, the contract will involve consulting with industry leaders to develop formulary adjustments, the analysis of wound care funding models, and developing educational materials for practitioners, followed by recommendations around government policy and legislation.
The province can extend the contract for two one-year extensions beyond the initial 12-month contract.
HOW’s software, how2trak, gives healthcare providers real-time, evidence-based direction wound care management, allowing patients to heal more quickly while also reducing costs to the overall system.
“I am incredibly proud of the accomplishments the HOW team has made in the past year and I feel we are well positioned to continue this momentum throughout 2016,” said McIsaac.
“HOW is leading the way in healthcare software solutions and as a result, we are helping patients to heal more quickly while helping doctors and nurses do their jobs more efficiently.”
HOW has offices in Albert, Ontario and British Columbia, and raised $1.5 million in venture capital funding during 2015.
According to the provincial government’s tender document, the extent of the second phase of the project will be based on the amount of funding available.


See original article in LINK Magazine
In late October 2015 leaders from the life sciences community across Atlantic Canada gathered at BioPort Atlantic, the annual life sciences industry event to discuss the future of the sector. The conference provided a forum to inform and inspire the next generation of life sciences entrepreneurs to develop their ideas, commercialize their technologies and build links within the region and abroad. The outcomes of those discussions shed light on the future economic growth of the sector, hinting at a sustainable and competitive economic landscape for companies in the region.
Ron Keefe
In Atlantic Canada, the commercial life sciences cluster employs thousands of people, generating over $500 million in sales revenue each year. One of the area’s most successful leaders Ron Keefe, CEO of Prince Edward Island based BioVectra Inc. attended BioPort this year as the keynote speaker. A former lawyer, Mr. Keefe made a career change and joined drug manufacturer BioVectra after seeing potential for significant growth in the global biotechnology and pharmaceutical industries. That decision would pay off a decade later when BioVectra was sold to Questcor Pharmaceuticals of Anaheim, California for $100 million.
During his time at BioPort Atlantic Mr. Keefe discussed the opportunities and obstacles that new entrepreneurs face in Atlantic Canada. As the CEO of the Regis Duffy BioScience Fund Inc., a private venture fund targeting science based businesses he knows one of the biggest struggles for new entrepreneurs is raising investment capital – a common issue in the region. In spite of the area’s challenges Mr. Keefe spoke optimistically about the future of the sector and the resilience of aspiring entrepreneurs.
“With limited resources Atlantic Canadians have persevered with a renewed entrepreneurial spirit and I really truly believe we will have a changed economy over the next ten years.”
To support entrepreneurs entering the market Mr. Keefe hopes to see an increased investment in infrastructure by government. With the creation of incubation centres and pilot scale facilities for the manufacturing sector he believes new entrepreneurs would have a strong foundation of support to innovate and bring their products to market faster – something he says would have benefited BioVectra in their early days.
Another local leader who came to inspire and motivate attendees at BioPort Atlantic was Marc St-Onge, Founder of Ascenta Health Ltd. and current CEO and Founder of Ascenta Skin. Appointed as the Honorary Conference Chair, St-Onge kicked off the conference with some key insights from his journey through entrepreneurship. He attributed much of his success to building a strong brand culture which helped him to sell his omega-3 fish oil supplement to customers seeking improved health and wellness.
St-Onge became committed to both validated science and healthy living after dealing with his own health struggles. Combining his entrepreneurial and research background, he seized opportunities to create sustainable and health focused products. Through Ascenta he was able to attract a growing market of people who were eager to support a health focused brand making it easier to attract talent, investors and sell his products. “Culture makes your organization solid, a company’s culture is their biggest asset” says St-Onge.
Michael Fergusson
To end off the conference attendees were introduced to a new presentation topic with a focus on healthcare’s digital future. The Digital Health presentation was added as an introduction to the emerging digital health sector focusing on areas of opportunity for Atlantic Canadian companies to solve health related issues using new technologies. With the region’s growing IT sector and flourishing health/life sciences industry the digital health presentation was a popular session for attendees.
Michael Fergusson, CEO and Founder of Vancouver based Ayogo lead the discussion on digital health at the conference. His company Ayogo created a technology that offers a digital platform for healthcare organizations that helps patients manage chronic illness. The company was named one of the 100 most innovative mHealth companies in the world, and Fergusson was recently named Ernst & Young’s Social Entrepreneur of the Year.
During his speech he spoke about the psychology behind the process of creating a tech solution for a healthcare issue. Through research he has learned to improve engagement with technology by appealing to people’s emotions and normal habits rather than to build a technology without those considerations. He attributed much of Ayogo’s success in the digital health space to this philosophy and hoped to impart that knowledge on Nova Scotia’s budding digital health community.

Each year BioPort Atlantic aims to educate, build awareness and generate and discuss opportunities to grow the life sciences industry in Atlantic Canada. As the sector has evolved the conference agenda has evolved with it, continuing to bring the latest topics and speakers to the region and inspire the next generation of entrepreneurs.

Welcome to our Newly Launched Website

To start off 2016 on the right foot, we planned a refreshed and modern new look for BioNova. Our goal with our new website was to better promote the life sciences sector in Nova Scotia and increase visibility and support for our members. We chose a visual display that will allow visitors to quickly learn about our sector, from the industries we serve to our members and the latest news and events surrounding them.
We welcome you to take the full tour and let us know if you have any feedback or changes you would  like to see for future updates. A website is always a work in progress and ours will evolve as the industry changes and we onboard new members. We look forward to hearing from you!
Contact us about our Website

FMI: Biostimulants Market Poised to Account for US$ 4,109.5 Mn By 2025

See original article
Demand for biostimulants is expected to surpass US$ 4 billion in revenues, according to a new research report by Future Market Insights (FMI). The report titled, “Biostimulants Market: Global Industry Analysis and Opportunity Assessment 2015-2025” forecasts the demand for biostimulants to expand at a CAGR of nearly 11% through 2025.
Biostimulants are finding increasing application in the agriculture sector owing to their environmentally-friendly and organic nature. Rising food demand is putting pressure on land and focus has shifted to enhancing the yield per hectare.
“Governments around the world are speeding up efforts to boost agricultural production. Use of biostimulants is being encouraged to improve the overall output, and this is expected to fuel demand in the near future”, said the FMI analyst who compiled the report.
Although FMI expects the demand for biostimulants to expand at a robust pace during the forecast period 2015-2025, certain factors can impede growth. “Lack of standardisation and slow pace of innovation are the key restraining factors for the global biostimulants market.”
Foliar Dominant Application Segment for Biostimulants
Biostimulants are used in foliar, seed, and soil; among these, use of biostimulants is highest in the foliar segment, accounting for nearly one-third market share in 2014. On the basis of crop type, use of biostimulants is predominant in row crops, and fruits and vegetables. Application of biostimulants in turf and ornamental is at a nascent stage currently. FMI forecasts the turf and ornamental segment to expand at a CAGR of over 6% during 2015-2025.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-354
Strong Demand for Acid-Based Biostimulants
Demand for acid-based biostimulants is higher than acid-based- and extract-based biostimulants, owing to easy availability of raw materials and higher efficiency. Biostimulants containing Vitamin B, chitin and chitosan are expected to gain traction during the forecast period.
Western Europe Most Lucrative Market
Western Europe is the largest market for biostimulants, accounting for over 30% market value share in 2014. Focus on enhancing yield per hectare coupled with government support are the key factors propelling the growth of the market in the region.
Asia Pacific Excluding Japan is emerging as a lucrative market for biostimulants. The agriculture sector in the region is witnessing a shift from traditional farming practices to use of technology and additives, owing to which biostimulants are expected to gain traction in the next decade.
Acadian Seaplants Limited, Biostadt India Limited, Omex Agrifluids Ltd., Italpollina Spa, Koppert B.V., BioAtlantis Ltd., Micromix Plant Health Limited, Trade Corporation International, Valagro S.p.A, Isagro S.p.A, Platform Specialty Products Corporation,  BASF SE, Novozymes A/S, Agrinos A/S and The Dow Chemical Company.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-354
Segmentation of the global biostimulants market:
By Application

  • Foliar
  • Soil
  • Seed

By Crop Type

  • Row
  • Fruits & vegetables
  • Turf & ornamental
  • Other crops

By Active Ingredient Type

  • Acid-based
  • Extract-based
  • Others

By Geography
Western Europe

  • EU-5 Countries
  • Nordic
  • Rest of Western Europe

North America

  • U.S.
  • Canada

Asia Pacific Excluding Japan (APEJ)

  • China
  • India
  • Oceania
  • Rest of APEJ

Latin America

  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America

Eastern Europe

  • Poland
  • Russia
  • Rest of Eastern Europe

Middle East and Africa

  • GCC
  • South Africa
  • Turkey
  • Rest of Middle East and Africa



NeuroQuest Press Release
February 9, 2016— NeuroQuest Inc. (www.neuroquest.ca), and its joint-venture partner Concept 2 Clinic Inc. (www.concept2clinic.com) (“Company”) today announced that the Canadian Intellectual Properties Office (“CIPO”) and the Korean Intellectual Property Office (“KIPO”) have issued the patents for the Company’s lead natural bioactive products.
“With these issuance’s in Canada and Korea, we will have very comprehensive intellectual property protection for our lead natural bioactive research programs. We intend to further enhance our intellectual property portfolio with additional patent applications in US, Europe, China and Japan throughout 2016 and beyond,” said Robert Cervelli, NeuroQuest’s Chief Executive Officer.
“Our Company’s medicinal chemistry program began with specific naturally occurring compounds which have prior evidence of efficacy and safety in both animal and human studies. These natural compounds are listed as GRAS (generally regarded as safe) by the US FDA, providing an excellent safety profile. PN34 is a naturally-occurring bioactive which is highly efficacious in relieving neuropathic and nociceptive pains. Unlike currently marketed neuropathic pain therapeutics, PN34 has no life-threatening side effects, and induces no numbing or burning sensation. These properties of PN34 appeal to current market needs, which place increasing pressure on drug safety,” said YC Lee,
Ph.D., Concept 2 Clinic’s Managing Director.
Canadian Patent Number CA 2676139 “Composition Comprising Terpene Compounds and Methods for Inhibiting Nerve Transmission”, was issued in February, 2016 and will expire in 2028. Korean Patent Number 10-1580857 “Composition Comprising Terpene Compounds and Methods for Inhibiting Nerve Transmission” was issued on December 22, 2015 and will expire in 2028.
About NeuroQuest Inc. and Concept 2 Clinic Inc.
NeuroQuest Inc. (www.neuroquest.ca) and its joint-venture partner, Concept 2 Clinic Inc.
(www.concept2clinic.com), are Canadian biotechnology companies located in Halifax and Toronto focused on developing prescription drugs from enhanced chemical modifications to natural bioactives for the treatment of neurological diseases. NeuroQuest and Concept 2 Clinic are seeking new approaches to modulation of nerve transmission with clinical applications particularly for neuropathic pain. The company focuses on a first-in-class small molecule drug discovery platform that is based on bioactives discovered in plant extracts showing efficacy for neuropathic pain. The company has a proprietary position in both natural bioactives for the consumer health market and new chemical entities (NCE’s) for out-license to the pharmaceutical industry.
For further information, please visit the Company’s website at www.neuroquest.ca;
www.concept2clinic.com or contact:
Mr. Robert Cervelli, President & CEO of NeuroQuest Inc.
001-902-222-4391 (direct)
Email: cervelli@neuroquest.ca
YC Lee, Ph.D. , Managing Director of Concept 2 Clinic Inc.
001-416-805-8573 (direct)
Email: yc.lee@concept2clinic.com